What Medicine Can Actually Do for Opioid Dependence

Understanding What Is Being Treated

Before evaluating treatment options, it helps to be precise about what opioid treatment is addressing. There are two related but distinct conditions:

Physical dependence is the body's biological adaptation to opioids. With consistent use, the brain down-regulates its own endorphin production and adjusts receptor sensitivity to accommodate the external supply. When the supply is removed, withdrawal occurs. Physical dependence is not a behavioral disorder. It is a physiological reality that can develop in anyone who takes opioids consistently, including patients who follow their prescription exactly as written.

Opioid use disorder (OUD) is a clinical diagnosis that includes compulsive use despite harmful consequences, loss of control, cravings, and dysfunction in social, occupational, or personal domains. OUD involves changes in brain circuits beyond simple receptor adaptation, including alterations in reward processing, motivation, and impulse control.

Every patient who presents for opioid treatment has physical dependence. Not every patient has opioid use disorder. The treatment plan should reflect which condition, or combination of conditions, is present. A person who is physically dependent but does not meet criteria for OUD may need a different approach than someone with a severe, longstanding use disorder. For a deeper discussion of how this distinction shapes treatment choices, see the homepage overview.

Inpatient Hospital-Based Medical Detox

Hospital-based medical detoxification is the process of clearing opioids from the body under continuous physician supervision in an inpatient medical setting. It is the most medically intensive form of detox available and is considered the safest environment for managing opioid withdrawal, particularly for patients with complex medical histories.

The Protocol

Upon admission, the patient undergoes a comprehensive medical evaluation including blood work, cardiac monitoring, and assessment of withdrawal severity using standardized scales such as the Clinical Opiate Withdrawal Scale (COWS). A physician develops an individualized detox protocol based on the substance used, the duration and severity of dependence, and any co-occurring medical conditions.

Medications commonly used during hospital detox include:

• Clonidine - an alpha-2 agonist that reduces autonomic withdrawal symptoms such as sweating, elevated heart rate, and agitation
• Benzodiazepines - used cautiously for severe anxiety, insomnia, and muscle spasms
• Anti-emetics - for nausea and vomiting
• Non-opioid analgesics - for muscle and bone pain
• Short opioid tapers - in some protocols, a controlled taper using a short-acting opioid or buprenorphine may be used to ease the transition

Vital signs are monitored continuously or at frequent intervals. Nursing staff provides 24-hour care. The acute withdrawal phase typically lasts five to ten days, depending on the substance. Fentanyl withdrawal may take longer due to the drug's accumulation in fatty tissue.

Who It Is For

Hospital-based detox is appropriate for patients who want to stop opioids entirely and need medical oversight during withdrawal. It is particularly recommended for patients with co-occurring medical conditions such as cardiovascular disease, diabetes, or respiratory conditions, patients with a history of complicated withdrawal, patients who have been unable to complete withdrawal in less supervised settings, and patients who are medically fragile or elderly.

What It Does and Does Not Do

Hospital detox resolves physical dependence. It clears the drug from the body and manages withdrawal safely. It does not, by itself, treat opioid use disorder. Detox is the beginning of treatment, not the treatment itself. Patients who complete hospital detox should have a structured post-detox plan in place, which may include naltrexone therapy, outpatient counseling, or residential rehabilitation. Relapse rates after detox alone are high, and the risk of overdose is elevated in the period immediately following detox because tolerance has been reduced. For more on how hospital detox fits into the broader continuum of care, see our inpatient vs outpatient guide.

Rapid Detox Under Sedation

Rapid detox under sedation is a specialized medical procedure designed to accelerate the opioid withdrawal process while the patient is under general anesthesia or deep sedation. It is performed in a hospital setting, typically in an intensive care unit or surgical suite, by a team that includes an anesthesiologist and an addiction medicine specialist.

The Procedure

The patient is admitted to the hospital and undergoes pre-procedure evaluation including cardiac assessment, blood work, and anesthesia clearance. Once under sedation, the medical team administers an opioid antagonist, typically naloxone or naltrexone, which rapidly displaces opioids from receptors. This triggers an accelerated withdrawal that occurs over a period of hours rather than days. Because the patient is sedated, they do not consciously experience the most severe withdrawal symptoms.

Throughout the procedure, vital signs are continuously monitored. IV fluids and electrolytes are administered. Medications are given to manage autonomic instability. After the acute phase, the patient is monitored in recovery and typically remains in the hospital for one to three days.

The Clinical Advantage

The primary advantage of rapid detox is that it compresses the worst phase of withdrawal into a controlled medical event. For many patients, the fear of withdrawal is the single greatest barrier to seeking treatment. Rapid detox removes that barrier. It also creates a clean bridge to naltrexone therapy, because the antagonist used during the procedure begins the receptor blockade that naltrexone will continue.

Programs such as the Waismann Method have refined this approach over decades, performing the procedure in accredited hospitals with full ICU-level support. Detailed clinical information is also available at rapiddetox.com.

Risks and Considerations

Rapid detox carries the risks associated with any procedure involving sedation: aspiration, cardiac events, and respiratory complications. These risks are mitigated by performing the procedure in a fully equipped hospital with experienced anesthesiology support. Rapid detox is not appropriate for all patients. Contraindications may include severe cardiac disease, respiratory insufficiency, and certain psychiatric conditions. A thorough medical evaluation is required before the procedure.

What It Does Not Do

Like all forms of detox, rapid detox resolves physical dependence but does not constitute complete treatment for opioid use disorder. Patients who undergo rapid detox should have a post-procedure plan that includes naltrexone maintenance, behavioral therapy, and ongoing medical follow-up. The value of rapid detox is that it can serve as an efficient starting point for a comprehensive treatment plan, not that it replaces one.

Naltrexone and Vivitrol

Naltrexone is an opioid antagonist. It binds to opioid receptors and blocks them without activating them. It produces no high, no sedation, no euphoria, and no physical dependence. It is fundamentally different from methadone and buprenorphine in both mechanism and clinical profile.

How It Works

Once naltrexone occupies opioid receptors, any opioid the person takes will be unable to produce its usual effect. The receptors are blocked. This removes the pharmacological incentive for relapse. If a person on naltrexone uses heroin or fentanyl, they will not feel the high. Over time, this decouples the association between opioid use and reward, which is one of the core drivers of addiction.

Naltrexone is available in two forms:

• Oral naltrexone - a daily pill, typically 50mg, taken each morning. Requires daily compliance.
• Vivitrol - an extended-release injectable form administered once per month by intramuscular injection. Eliminates the issue of daily compliance and provides consistent receptor blockade for approximately 30 days.

Requirements

Naltrexone cannot be started while opioids are still present in the body. Doing so will cause precipitated withdrawal, a sudden and severe withdrawal syndrome caused by the abrupt displacement of opioids from receptors. The patient must be fully detoxed before naltrexone can be initiated. For short-acting opioids, this typically means seven to ten days of abstinence. For long-acting opioids like methadone, ten to fourteen days may be required. For fentanyl, the waiting period may be longer. A naloxone challenge test can confirm that receptors are clear before the first dose.

Who It Is For

Naltrexone is best suited for patients who have completed detox and want to maintain abstinence without taking an opioid-based medication. It is a strong option for patients who are motivated, have a supportive environment, and want to achieve full opioid independence. The injectable form, Vivitrol, is particularly useful for patients who may struggle with daily medication adherence. Naltrexone is not appropriate for patients who are still actively using opioids or who have not completed detoxification.

Maintenance Medications: Methadone and Buprenorphine

Methadone and buprenorphine are the most widely prescribed medications for opioid dependence in the United States. Both are opioids. Both activate opioid receptors. Both prevent withdrawal and reduce cravings by maintaining a controlled level of opioid activity in the brain. They are categorized as medication-assisted treatment (MAT), a term that reflects the clinical consensus that these medications, when combined with counseling, improve outcomes for people with opioid use disorder.

Methadone

Methadone is a full opioid agonist, meaning it fully activates opioid receptors. It is dispensed through federally regulated opioid treatment programs (OTPs) and, in most cases, requires daily visits to a clinic for supervised dosing, at least in the early phases of treatment. Methadone has the longest track record of any medication for opioid dependence, with research dating to the 1960s. It is effective at suppressing withdrawal, reducing cravings, and reducing illicit opioid use. It is also associated with reduced rates of HIV transmission, criminal activity, and overdose death.

The limitations of methadone include the daily clinic visits required for most patients, the potential for diversion, and the fact that methadone itself can cause overdose if taken in excessive doses or combined with other central nervous system depressants. Methadone withdrawal, when a patient decides to taper off, can be prolonged and difficult, sometimes lasting weeks to months.

Buprenorphine (Suboxone, Subutex, Sublocade)

Buprenorphine is a partial opioid agonist. It activates opioid receptors but with a ceiling effect, meaning that beyond a certain dose, additional buprenorphine does not produce increased opioid effects. This ceiling reduces the risk of overdose compared to full agonists. Buprenorphine can be prescribed in office-based settings, making it more accessible than methadone for many patients.

Suboxone combines buprenorphine with naloxone, an antagonist that is included to deter misuse by injection. Sublocade is a monthly injectable form that provides sustained release. Buprenorphine is effective at preventing withdrawal and reducing cravings. It has a lower abuse potential than methadone but does carry a risk of diversion and misuse, particularly in its earlier formulations.

The Honest Assessment

Methadone and buprenorphine save lives. The evidence is clear. For patients with severe opioid use disorder who are at high risk of overdose, these medications provide stability that no other treatment can match in the short term. They reduce mortality. They reduce disease transmission. They allow people to function, work, and maintain relationships.

It is equally true that both medications maintain physical opioid dependence. A patient on long-term methadone or buprenorphine who stops taking the medication will experience withdrawal. These medications manage dependence. They do not resolve it. For some patients, this trade-off is acceptable and even preferable. For others, it is not.

Some patients on maintenance medications will eventually want to taper off. Tapering from methadone or buprenorphine should be done slowly, under medical supervision, and with a clear post-taper plan that may include naltrexone and behavioral support. Abrupt discontinuation is dangerous and is associated with high relapse rates.

Behavioral Therapy and Psychiatric Care

Medications address the neurochemistry of opioid dependence. Behavioral therapy addresses the psychology. The two are complementary, and the most effective treatment plans typically include both.

Cognitive Behavioral Therapy (CBT)

CBT helps patients identify thought patterns and situations that trigger opioid use, and develop practical strategies to manage them. It is structured, time-limited, and has a strong evidence base for substance use disorders. CBT teaches skills that remain useful long after therapy ends.

Motivational Interviewing (MI)

MI is a collaborative, goal-oriented counseling style designed to strengthen a person's own motivation for change. It is particularly useful in the early stages of treatment when ambivalence about recovery is common. MI does not confront or pressure. It helps the patient articulate their own reasons for seeking change.

Trauma-Informed Care

Many people with opioid dependence have histories of trauma, including childhood abuse, neglect, violence, or other adverse experiences. Trauma-informed care recognizes this and integrates trauma treatment into the recovery process rather than treating substance use in isolation. Approaches like EMDR (Eye Movement Desensitization and Reprocessing) and trauma-focused CBT can be incorporated into the treatment plan.

Psychiatric Evaluation and Co-Occurring Disorders

Depression, anxiety, PTSD, bipolar disorder, and other psychiatric conditions frequently co-occur with opioid dependence. A psychiatric evaluation should be part of any comprehensive treatment plan. Untreated mental health conditions are among the strongest predictors of relapse. Medications for co-occurring disorders, such as antidepressants or mood stabilizers, may be an important component of the overall treatment plan.

Peer Support

Recovery coaches, mutual aid groups, sober living communities, and peer-run recovery centers provide practical and emotional support that complements clinical treatment. Peer support is not a substitute for medical care, but it plays a valuable role in sustaining motivation, building community, and navigating the daily challenges of early recovery. For more on how therapy and counseling fit into the treatment process, see what to expect in treatment.

The Principle of Individualized Care

No single treatment works for everyone. The substance matters. The duration and severity of use matter. Co-occurring psychiatric and medical conditions matter. The patient's living situation, support system, employment, and personal goals all matter. A 25-year-old who has been using fentanyl for six months is in a different clinical situation than a 60-year-old who has been on prescription opioids for a decade.

The ASAM Criteria, developed by the American Society of Addiction Medicine, provides a standardized framework for matching patients to the appropriate level and type of care. It evaluates six dimensions: withdrawal potential, biomedical conditions, emotional and behavioral conditions, readiness to change, relapse potential, and recovery environment.

Treatment should never be prescribed by default. The question should always be: what does this specific patient need, at this specific point in time, given their specific circumstances? That is the standard every treatment provider should be held to, and it is the standard every patient and family has the right to expect.

What is the difference between opioid detox and opioid treatment?

Detoxification is the process of clearing opioids from the body while managing withdrawal symptoms. It addresses physical dependence, which is the body's biological adaptation to the presence of opioids. Treatment is the broader clinical effort to address the full scope of opioid use disorder, including the behavioral, psychological, and social dimensions. Detox resolves the immediate physical crisis. Treatment addresses the underlying condition. Detox alone has high relapse rates because it does not change the neurological patterns, environmental triggers, or psychological factors that drive continued use. The most effective approach is detox followed by a structured treatment plan that may include naltrexone, behavioral therapy, psychiatric care, or maintenance medication.

How does hospital-based medical detox differ from going to a rehab facility?

Hospital-based medical detox takes place in a hospital or accredited medical facility with physician oversight, nursing staff, and the ability to manage medical emergencies. It is focused on the acute withdrawal phase, typically lasting five to ten days. A rehab facility, or residential treatment center, provides a longer-term therapeutic environment, usually 30 to 90 days, that includes counseling, group therapy, life skills training, and aftercare planning. Rehab addresses the behavioral and psychological dimensions of opioid use disorder. Many patients complete hospital detox first and then transition to residential rehabilitation. Some residential programs include on-site medical detox, but the medical resources available in a hospital setting are generally more comprehensive, particularly for patients with co-occurring medical conditions.

What is precipitated withdrawal and why does it matter?

Precipitated withdrawal occurs when an opioid antagonist or partial agonist is introduced while full agonist opioids are still occupying receptors. The incoming medication displaces the opioid from the receptors faster than the body can adjust, causing sudden and severe withdrawal symptoms. This can happen when buprenorphine (Suboxone) is started too soon after the last dose of heroin, fentanyl, or a prescription opioid. It can also occur during rapid detox if the protocol is not properly managed. Precipitated withdrawal is more intense than natural withdrawal and can include severe cramping, vomiting, diarrhea, and extreme agitation. To avoid it, clinicians use standardized induction protocols that require a sufficient period of abstinence before starting antagonist or partial agonist medications. The specific timing depends on the opioid used, as fentanyl in particular requires a longer washout period.

Can a person on Suboxone still become addicted to opioids?

Buprenorphine, the active opioid in Suboxone, is a partial agonist. It activates opioid receptors but to a lesser degree than full agonists like heroin or fentanyl. While buprenorphine reduces cravings and prevents withdrawal, a person taking it is still physically dependent on an opioid. If buprenorphine is stopped abruptly, withdrawal will occur. Whether a person on Suboxone can develop addictive patterns depends on how the medication is used. When taken as prescribed under medical supervision, buprenorphine is generally stable and does not produce the euphoric highs associated with misuse. However, buprenorphine can be misused, particularly in its non-film formulations, and diversion does occur. The key distinction is that Suboxone manages dependence, it does not eliminate it. Patients should understand this when making long-term treatment decisions.

How long after stopping opioids can naltrexone be started?

Naltrexone requires that all opioids be fully cleared from the body before it can be safely administered. If naltrexone is given while opioids are still present on receptors, it will cause precipitated withdrawal. For short-acting opioids like heroin or oxycodone, a minimum of seven to ten days of abstinence is typically required. For long-acting opioids like methadone, the waiting period may be 10 to 14 days or longer. For fentanyl, which accumulates in body fat and can be released slowly, some clinicians recommend waiting even longer. A naloxone challenge test can be administered before starting naltrexone to confirm that opioid receptors are clear. In the context of rapid detox under sedation, the transition to naltrexone can sometimes be accelerated because the detox process itself is compressed.

Is there a treatment approach that uses no opioids at all?

Yes. A treatment pathway that uses no opioids would typically involve medically supervised detoxification to clear the opioid from the body, followed by naltrexone (an opioid antagonist that is not itself an opioid) to prevent relapse, combined with behavioral therapy and psychiatric support. This approach achieves full opioid independence, meaning the patient is not taking any opioid-based medication on an ongoing basis. It is best suited for patients who have completed detox successfully, are medically stable, have a supportive living environment, and are motivated to maintain abstinence. Not every patient is a candidate for this pathway, but for those who are, it offers a treatment model that does not involve ongoing opioid dependence of any kind.

Does rapid detox under sedation produce better long-term outcomes?

Rapid detox under sedation shortens the acute withdrawal phase and eliminates the patient's conscious experience of the worst symptoms, which can improve the willingness to initiate treatment and the comfort of the detox process. However, rapid detox by itself, like any form of detox, is not sufficient for long-term recovery. Long-term outcomes depend on what happens after detox: whether the patient begins naltrexone, engages in behavioral therapy, receives psychiatric care if needed, and has a stable recovery environment. The advantage of rapid detox is that it can serve as an efficient on-ramp to naltrexone therapy, since the detox process is completed quickly and the transition to an antagonist medication can begin sooner. Patients who complete rapid detox and immediately begin naltrexone with ongoing therapeutic support have a structured path toward sustained recovery.